[GetPortalCommentsPageByObjectIdResponse(id=2194005, encodeId=c72021940051b, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/a740eabd21e54f09ba6a274bd9a74985-9iEgmowY5Bs2.jpg, createdBy=7dec9219365, createdName=Tou18389577351, createdTime=Tue Mar 19 09:33:59 CST 2024, time=1小时前, status=0, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193895, encodeId=aa8c2193895cc, content=审稿速度:24.0 | 投稿命中率:50.0<br>偏重的研究方向:数据分析<br>经验分享:用了一年多时间,太不容易了,分享一下过程吧<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>18 Mar 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>18 Mar 2024<br>Submission under peer review<br>25 Feb 2024<br>Submission passed technical check<br>25 Feb 2024<br>Amendment received<br>24 Feb 2024<br>Revision received<br>23 Feb 2024<br>Submission under peer review<br>21 Feb 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>21 Feb 2023<br>Submission is under technical check<br>20 Feb 2023<br>Submission received<br>Submission status Date<br>Submission received<br>20 Feb 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f83c4883792, createdName=SENOMEGA, createdTime=Mon Mar 18 15:21:02 CST 2024, time=19小时前, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2178836, encodeId=212721e883660, content=偏重的研究方向:生物信息学;肿瘤;Cancer<br>经验分享:- [ ] 2023.12.26 submission received
- [ ] 2023.12.26 submission is under technical check
- [ ] 2023.12.27 submission passed technical check
- [ ] 2023.12.27 editor invited
- [ ] 2023.12.27 editor assigned
- [ ] 2023.12.27 reviewers invited(3)
- [ ] 2023.12.27 1 reviewer(s) accepted
- [ ] 2023.12.30 2 reviewer(s) accepted (Awaiting their report), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240102/21c3548d3cdf4d768708708330c1b141/805c04b8c592400eb28358eb81f1a145.jpg, createdBy=4a299119890, createdName=Dehors, createdTime=Tue Jan 02 18:33:59 CST 2024, time=2024-01-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192926, encodeId=69e621929264f, content=大佬们,现在版面费是第三方收取么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqpapZYXCJZ2AkkJ5Gps0ysAzZE4zgb2VXFGn2ZHyMj98TIQpsx3yxTicaD0m42xk9m1vRtBPgS7TQ/132, createdBy=4b552425875, createdName=ms7957059236203375, createdTime=Wed Mar 13 10:38:38 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2193635, encodeId=dd73219363538, content=偏重的研究方向:肿瘤<br>经验分享:有问题可以聊聊 可稳妥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Sat Mar 16 21:13:02 CST 2024, time=2024-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182530, encodeId=53c4218253026, content=偏重的研究方向:临床预测模型<br>经验分享:Submission under peer review<br>14 Dec 2023<br>Submission passed technical check<br>14 Dec 2023<br>Amendment received<br>14 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>Submission under peer review一直没有变化,是不是连审稿人都没邀请啊?不会被忘了吧。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa979032293, createdName=ms2000000264173426, createdTime=Fri Jan 19 00:15:20 CST 2024, time=2024-01-19, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2192756, encodeId=a4772192e56a0, content=偏重的研究方向:肿瘤<br>经验分享:比较nice,有办法可以accept,没投的可以聊聊,速度也挺快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Tue Mar 12 14:18:54 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193260, encodeId=55b72193260af, content=偏重的研究方向:肿瘤<br>经验分享:最近大家的状态都乱码了,大家都有点慌,我发邮件问了编辑,编辑也回复的,附在下边。我的理解是今年sr的系统应该是换状态了,现在的这个状态应该是包含了之前我们见过的很多状态,耐心等待吧,有消息应该会通知到邮箱
Dear Prof.,
Thank you for your email and please accept my sincerest apologies for the lack of update on your paper. Your manuscript has cleared the quality check stage and it is going through the peer review process. So afar we have secured one reviewer and the editor is inviting more reviewers in order to sure at least one more reviewer.
I completely understand that this delay is unacceptable and I cannot apologise enough for this. Please be assured that we are always in regular contact with the handling Editor and doing all we can to ensure your manuscript is expedited through the publishing process as swiftly as possible. We hope to get a decision to you soon and your patience while we do this will be greatly appreciated.
Please do not hesitate to contact us again if there is anything we may be able to help you with, and please accept my apologies once more.
Kind Regards,
Prasad Bhalerao, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=611f6487300, createdName=ms4000001202980961, createdTime=Thu Mar 14 19:13:57 CST 2024, time=2024-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192732, encodeId=d4962192e3210, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:分子;细胞<br>经验分享:23年9月开始投的,一直到现在24.3.12都一直没用动静,之前是18个同行评审,现在也看不见,中途出现过一个审稿人意见,只有一个,但是系统上看不见,现在也没有显示有审稿意见了,这也太慢了,都想投其他期刊了,又感觉等这么久就白费了<br>Submission history<br>Peer review<br>Submission status Date<br>Submission under peer review<br>06 Oct 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>06 Oct 2023<br>Amendment received<br>06 Oct 2023<br>Submission is under technical check<br>18 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>18 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4248263748, createdName=ms9000001661382603, createdTime=Tue Mar 12 11:13:29 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2173392, encodeId=267721e339254, content=想问下大佬们,到这个阶段之后,后续会有editer has been invited 或者多少多少reviewers has been invited吗?还是就过几个礼拜直接到decision了?
We will now find the most suitable editor to manage the next steps of your submission. If your submission is successful, they will invite reviewers to peer review your work. This process can take a few weeks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Wed Dec 06 23:30:26 CST 2023, time=2023-12-06, status=1, ipAttribution=上海)]
[GetPortalCommentsPageByObjectIdResponse(id=2194005, encodeId=c72021940051b, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/a740eabd21e54f09ba6a274bd9a74985-9iEgmowY5Bs2.jpg, createdBy=7dec9219365, createdName=Tou18389577351, createdTime=Tue Mar 19 09:33:59 CST 2024, time=1小时前, status=0, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193895, encodeId=aa8c2193895cc, content=审稿速度:24.0 | 投稿命中率:50.0<br>偏重的研究方向:数据分析<br>经验分享:用了一年多时间,太不容易了,分享一下过程吧<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>18 Mar 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>18 Mar 2024<br>Submission under peer review<br>25 Feb 2024<br>Submission passed technical check<br>25 Feb 2024<br>Amendment received<br>24 Feb 2024<br>Revision received<br>23 Feb 2024<br>Submission under peer review<br>21 Feb 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>21 Feb 2023<br>Submission is under technical check<br>20 Feb 2023<br>Submission received<br>Submission status Date<br>Submission received<br>20 Feb 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f83c4883792, createdName=SENOMEGA, createdTime=Mon Mar 18 15:21:02 CST 2024, time=19小时前, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2178836, encodeId=212721e883660, content=偏重的研究方向:生物信息学;肿瘤;Cancer<br>经验分享:- [ ] 2023.12.26 submission received
- [ ] 2023.12.26 submission is under technical check
- [ ] 2023.12.27 submission passed technical check
- [ ] 2023.12.27 editor invited
- [ ] 2023.12.27 editor assigned
- [ ] 2023.12.27 reviewers invited(3)
- [ ] 2023.12.27 1 reviewer(s) accepted
- [ ] 2023.12.30 2 reviewer(s) accepted (Awaiting their report), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240102/21c3548d3cdf4d768708708330c1b141/805c04b8c592400eb28358eb81f1a145.jpg, createdBy=4a299119890, createdName=Dehors, createdTime=Tue Jan 02 18:33:59 CST 2024, time=2024-01-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192926, encodeId=69e621929264f, content=大佬们,现在版面费是第三方收取么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqpapZYXCJZ2AkkJ5Gps0ysAzZE4zgb2VXFGn2ZHyMj98TIQpsx3yxTicaD0m42xk9m1vRtBPgS7TQ/132, createdBy=4b552425875, createdName=ms7957059236203375, createdTime=Wed Mar 13 10:38:38 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2193635, encodeId=dd73219363538, content=偏重的研究方向:肿瘤<br>经验分享:有问题可以聊聊 可稳妥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Sat Mar 16 21:13:02 CST 2024, time=2024-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182530, encodeId=53c4218253026, content=偏重的研究方向:临床预测模型<br>经验分享:Submission under peer review<br>14 Dec 2023<br>Submission passed technical check<br>14 Dec 2023<br>Amendment received<br>14 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>Submission under peer review一直没有变化,是不是连审稿人都没邀请啊?不会被忘了吧。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa979032293, createdName=ms2000000264173426, createdTime=Fri Jan 19 00:15:20 CST 2024, time=2024-01-19, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2192756, encodeId=a4772192e56a0, content=偏重的研究方向:肿瘤<br>经验分享:比较nice,有办法可以accept,没投的可以聊聊,速度也挺快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Tue Mar 12 14:18:54 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193260, encodeId=55b72193260af, content=偏重的研究方向:肿瘤<br>经验分享:最近大家的状态都乱码了,大家都有点慌,我发邮件问了编辑,编辑也回复的,附在下边。我的理解是今年sr的系统应该是换状态了,现在的这个状态应该是包含了之前我们见过的很多状态,耐心等待吧,有消息应该会通知到邮箱
Dear Prof.,
Thank you for your email and please accept my sincerest apologies for the lack of update on your paper. Your manuscript has cleared the quality check stage and it is going through the peer review process. So afar we have secured one reviewer and the editor is inviting more reviewers in order to sure at least one more reviewer.
I completely understand that this delay is unacceptable and I cannot apologise enough for this. Please be assured that we are always in regular contact with the handling Editor and doing all we can to ensure your manuscript is expedited through the publishing process as swiftly as possible. We hope to get a decision to you soon and your patience while we do this will be greatly appreciated.
Please do not hesitate to contact us again if there is anything we may be able to help you with, and please accept my apologies once more.
Kind Regards,
Prasad Bhalerao, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=611f6487300, createdName=ms4000001202980961, createdTime=Thu Mar 14 19:13:57 CST 2024, time=2024-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192732, encodeId=d4962192e3210, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:分子;细胞<br>经验分享:23年9月开始投的,一直到现在24.3.12都一直没用动静,之前是18个同行评审,现在也看不见,中途出现过一个审稿人意见,只有一个,但是系统上看不见,现在也没有显示有审稿意见了,这也太慢了,都想投其他期刊了,又感觉等这么久就白费了<br>Submission history<br>Peer review<br>Submission status Date<br>Submission under peer review<br>06 Oct 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>06 Oct 2023<br>Amendment received<br>06 Oct 2023<br>Submission is under technical check<br>18 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>18 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4248263748, createdName=ms9000001661382603, createdTime=Tue Mar 12 11:13:29 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2173392, encodeId=267721e339254, content=想问下大佬们,到这个阶段之后,后续会有editer has been invited 或者多少多少reviewers has been invited吗?还是就过几个礼拜直接到decision了?
We will now find the most suitable editor to manage the next steps of your submission. If your submission is successful, they will invite reviewers to peer review your work. This process can take a few weeks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Wed Dec 06 23:30:26 CST 2023, time=2023-12-06, status=1, ipAttribution=上海)]
审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向:数据分析 经验分享:用了一年多时间,太不容易了,分享一下过程吧 Publishing and rights Submission status Date Submission is in publishing and rights 18 Mar 2024 Peer review Submission status Date Submission accepted 18 Mar 2024 Submission under peer review 25 Feb 2024 Submission passed technical check 25 Feb 2024 Amendment received 24 Feb 2024 Revision received 23 Feb 2024 Submission under peer review 21 Feb 2023 Technical check Submission status Date Submission passed technical check 21 Feb 2023 Submission is under technical check 20 Feb 2023 Submission received Submission status Date Submission received 20 Feb 2023
[GetPortalCommentsPageByObjectIdResponse(id=2194005, encodeId=c72021940051b, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/a740eabd21e54f09ba6a274bd9a74985-9iEgmowY5Bs2.jpg, createdBy=7dec9219365, createdName=Tou18389577351, createdTime=Tue Mar 19 09:33:59 CST 2024, time=1小时前, status=0, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193895, encodeId=aa8c2193895cc, content=审稿速度:24.0 | 投稿命中率:50.0<br>偏重的研究方向:数据分析<br>经验分享:用了一年多时间,太不容易了,分享一下过程吧<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>18 Mar 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>18 Mar 2024<br>Submission under peer review<br>25 Feb 2024<br>Submission passed technical check<br>25 Feb 2024<br>Amendment received<br>24 Feb 2024<br>Revision received<br>23 Feb 2024<br>Submission under peer review<br>21 Feb 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>21 Feb 2023<br>Submission is under technical check<br>20 Feb 2023<br>Submission received<br>Submission status Date<br>Submission received<br>20 Feb 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f83c4883792, createdName=SENOMEGA, createdTime=Mon Mar 18 15:21:02 CST 2024, time=19小时前, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2178836, encodeId=212721e883660, content=偏重的研究方向:生物信息学;肿瘤;Cancer<br>经验分享:- [ ] 2023.12.26 submission received
- [ ] 2023.12.26 submission is under technical check
- [ ] 2023.12.27 submission passed technical check
- [ ] 2023.12.27 editor invited
- [ ] 2023.12.27 editor assigned
- [ ] 2023.12.27 reviewers invited(3)
- [ ] 2023.12.27 1 reviewer(s) accepted
- [ ] 2023.12.30 2 reviewer(s) accepted (Awaiting their report), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240102/21c3548d3cdf4d768708708330c1b141/805c04b8c592400eb28358eb81f1a145.jpg, createdBy=4a299119890, createdName=Dehors, createdTime=Tue Jan 02 18:33:59 CST 2024, time=2024-01-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192926, encodeId=69e621929264f, content=大佬们,现在版面费是第三方收取么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqpapZYXCJZ2AkkJ5Gps0ysAzZE4zgb2VXFGn2ZHyMj98TIQpsx3yxTicaD0m42xk9m1vRtBPgS7TQ/132, createdBy=4b552425875, createdName=ms7957059236203375, createdTime=Wed Mar 13 10:38:38 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2193635, encodeId=dd73219363538, content=偏重的研究方向:肿瘤<br>经验分享:有问题可以聊聊 可稳妥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Sat Mar 16 21:13:02 CST 2024, time=2024-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182530, encodeId=53c4218253026, content=偏重的研究方向:临床预测模型<br>经验分享:Submission under peer review<br>14 Dec 2023<br>Submission passed technical check<br>14 Dec 2023<br>Amendment received<br>14 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>Submission under peer review一直没有变化,是不是连审稿人都没邀请啊?不会被忘了吧。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa979032293, createdName=ms2000000264173426, createdTime=Fri Jan 19 00:15:20 CST 2024, time=2024-01-19, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2192756, encodeId=a4772192e56a0, content=偏重的研究方向:肿瘤<br>经验分享:比较nice,有办法可以accept,没投的可以聊聊,速度也挺快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Tue Mar 12 14:18:54 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193260, encodeId=55b72193260af, content=偏重的研究方向:肿瘤<br>经验分享:最近大家的状态都乱码了,大家都有点慌,我发邮件问了编辑,编辑也回复的,附在下边。我的理解是今年sr的系统应该是换状态了,现在的这个状态应该是包含了之前我们见过的很多状态,耐心等待吧,有消息应该会通知到邮箱
Dear Prof.,
Thank you for your email and please accept my sincerest apologies for the lack of update on your paper. Your manuscript has cleared the quality check stage and it is going through the peer review process. So afar we have secured one reviewer and the editor is inviting more reviewers in order to sure at least one more reviewer.
I completely understand that this delay is unacceptable and I cannot apologise enough for this. Please be assured that we are always in regular contact with the handling Editor and doing all we can to ensure your manuscript is expedited through the publishing process as swiftly as possible. We hope to get a decision to you soon and your patience while we do this will be greatly appreciated.
Please do not hesitate to contact us again if there is anything we may be able to help you with, and please accept my apologies once more.
Kind Regards,
Prasad Bhalerao, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=611f6487300, createdName=ms4000001202980961, createdTime=Thu Mar 14 19:13:57 CST 2024, time=2024-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192732, encodeId=d4962192e3210, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:分子;细胞<br>经验分享:23年9月开始投的,一直到现在24.3.12都一直没用动静,之前是18个同行评审,现在也看不见,中途出现过一个审稿人意见,只有一个,但是系统上看不见,现在也没有显示有审稿意见了,这也太慢了,都想投其他期刊了,又感觉等这么久就白费了<br>Submission history<br>Peer review<br>Submission status Date<br>Submission under peer review<br>06 Oct 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>06 Oct 2023<br>Amendment received<br>06 Oct 2023<br>Submission is under technical check<br>18 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>18 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4248263748, createdName=ms9000001661382603, createdTime=Tue Mar 12 11:13:29 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2173392, encodeId=267721e339254, content=想问下大佬们,到这个阶段之后,后续会有editer has been invited 或者多少多少reviewers has been invited吗?还是就过几个礼拜直接到decision了?
We will now find the most suitable editor to manage the next steps of your submission. If your submission is successful, they will invite reviewers to peer review your work. This process can take a few weeks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Wed Dec 06 23:30:26 CST 2023, time=2023-12-06, status=1, ipAttribution=上海)]
[GetPortalCommentsPageByObjectIdResponse(id=2194005, encodeId=c72021940051b, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/a740eabd21e54f09ba6a274bd9a74985-9iEgmowY5Bs2.jpg, createdBy=7dec9219365, createdName=Tou18389577351, createdTime=Tue Mar 19 09:33:59 CST 2024, time=1小时前, status=0, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193895, encodeId=aa8c2193895cc, content=审稿速度:24.0 | 投稿命中率:50.0<br>偏重的研究方向:数据分析<br>经验分享:用了一年多时间,太不容易了,分享一下过程吧<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>18 Mar 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>18 Mar 2024<br>Submission under peer review<br>25 Feb 2024<br>Submission passed technical check<br>25 Feb 2024<br>Amendment received<br>24 Feb 2024<br>Revision received<br>23 Feb 2024<br>Submission under peer review<br>21 Feb 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>21 Feb 2023<br>Submission is under technical check<br>20 Feb 2023<br>Submission received<br>Submission status Date<br>Submission received<br>20 Feb 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f83c4883792, createdName=SENOMEGA, createdTime=Mon Mar 18 15:21:02 CST 2024, time=19小时前, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2178836, encodeId=212721e883660, content=偏重的研究方向:生物信息学;肿瘤;Cancer<br>经验分享:- [ ] 2023.12.26 submission received
- [ ] 2023.12.26 submission is under technical check
- [ ] 2023.12.27 submission passed technical check
- [ ] 2023.12.27 editor invited
- [ ] 2023.12.27 editor assigned
- [ ] 2023.12.27 reviewers invited(3)
- [ ] 2023.12.27 1 reviewer(s) accepted
- [ ] 2023.12.30 2 reviewer(s) accepted (Awaiting their report), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240102/21c3548d3cdf4d768708708330c1b141/805c04b8c592400eb28358eb81f1a145.jpg, createdBy=4a299119890, createdName=Dehors, createdTime=Tue Jan 02 18:33:59 CST 2024, time=2024-01-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192926, encodeId=69e621929264f, content=大佬们,现在版面费是第三方收取么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqpapZYXCJZ2AkkJ5Gps0ysAzZE4zgb2VXFGn2ZHyMj98TIQpsx3yxTicaD0m42xk9m1vRtBPgS7TQ/132, createdBy=4b552425875, createdName=ms7957059236203375, createdTime=Wed Mar 13 10:38:38 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2193635, encodeId=dd73219363538, content=偏重的研究方向:肿瘤<br>经验分享:有问题可以聊聊 可稳妥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Sat Mar 16 21:13:02 CST 2024, time=2024-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182530, encodeId=53c4218253026, content=偏重的研究方向:临床预测模型<br>经验分享:Submission under peer review<br>14 Dec 2023<br>Submission passed technical check<br>14 Dec 2023<br>Amendment received<br>14 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>Submission under peer review一直没有变化,是不是连审稿人都没邀请啊?不会被忘了吧。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa979032293, createdName=ms2000000264173426, createdTime=Fri Jan 19 00:15:20 CST 2024, time=2024-01-19, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2192756, encodeId=a4772192e56a0, content=偏重的研究方向:肿瘤<br>经验分享:比较nice,有办法可以accept,没投的可以聊聊,速度也挺快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Tue Mar 12 14:18:54 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193260, encodeId=55b72193260af, content=偏重的研究方向:肿瘤<br>经验分享:最近大家的状态都乱码了,大家都有点慌,我发邮件问了编辑,编辑也回复的,附在下边。我的理解是今年sr的系统应该是换状态了,现在的这个状态应该是包含了之前我们见过的很多状态,耐心等待吧,有消息应该会通知到邮箱
Dear Prof.,
Thank you for your email and please accept my sincerest apologies for the lack of update on your paper. Your manuscript has cleared the quality check stage and it is going through the peer review process. So afar we have secured one reviewer and the editor is inviting more reviewers in order to sure at least one more reviewer.
I completely understand that this delay is unacceptable and I cannot apologise enough for this. Please be assured that we are always in regular contact with the handling Editor and doing all we can to ensure your manuscript is expedited through the publishing process as swiftly as possible. We hope to get a decision to you soon and your patience while we do this will be greatly appreciated.
Please do not hesitate to contact us again if there is anything we may be able to help you with, and please accept my apologies once more.
Kind Regards,
Prasad Bhalerao, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=611f6487300, createdName=ms4000001202980961, createdTime=Thu Mar 14 19:13:57 CST 2024, time=2024-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192732, encodeId=d4962192e3210, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:分子;细胞<br>经验分享:23年9月开始投的,一直到现在24.3.12都一直没用动静,之前是18个同行评审,现在也看不见,中途出现过一个审稿人意见,只有一个,但是系统上看不见,现在也没有显示有审稿意见了,这也太慢了,都想投其他期刊了,又感觉等这么久就白费了<br>Submission history<br>Peer review<br>Submission status Date<br>Submission under peer review<br>06 Oct 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>06 Oct 2023<br>Amendment received<br>06 Oct 2023<br>Submission is under technical check<br>18 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>18 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4248263748, createdName=ms9000001661382603, createdTime=Tue Mar 12 11:13:29 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2173392, encodeId=267721e339254, content=想问下大佬们,到这个阶段之后,后续会有editer has been invited 或者多少多少reviewers has been invited吗?还是就过几个礼拜直接到decision了?
We will now find the most suitable editor to manage the next steps of your submission. If your submission is successful, they will invite reviewers to peer review your work. This process can take a few weeks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Wed Dec 06 23:30:26 CST 2023, time=2023-12-06, status=1, ipAttribution=上海)]
[GetPortalCommentsPageByObjectIdResponse(id=2194005, encodeId=c72021940051b, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/a740eabd21e54f09ba6a274bd9a74985-9iEgmowY5Bs2.jpg, createdBy=7dec9219365, createdName=Tou18389577351, createdTime=Tue Mar 19 09:33:59 CST 2024, time=1小时前, status=0, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193895, encodeId=aa8c2193895cc, content=审稿速度:24.0 | 投稿命中率:50.0<br>偏重的研究方向:数据分析<br>经验分享:用了一年多时间,太不容易了,分享一下过程吧<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>18 Mar 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>18 Mar 2024<br>Submission under peer review<br>25 Feb 2024<br>Submission passed technical check<br>25 Feb 2024<br>Amendment received<br>24 Feb 2024<br>Revision received<br>23 Feb 2024<br>Submission under peer review<br>21 Feb 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>21 Feb 2023<br>Submission is under technical check<br>20 Feb 2023<br>Submission received<br>Submission status Date<br>Submission received<br>20 Feb 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f83c4883792, createdName=SENOMEGA, createdTime=Mon Mar 18 15:21:02 CST 2024, time=19小时前, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2178836, encodeId=212721e883660, content=偏重的研究方向:生物信息学;肿瘤;Cancer<br>经验分享:- [ ] 2023.12.26 submission received
- [ ] 2023.12.26 submission is under technical check
- [ ] 2023.12.27 submission passed technical check
- [ ] 2023.12.27 editor invited
- [ ] 2023.12.27 editor assigned
- [ ] 2023.12.27 reviewers invited(3)
- [ ] 2023.12.27 1 reviewer(s) accepted
- [ ] 2023.12.30 2 reviewer(s) accepted (Awaiting their report), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240102/21c3548d3cdf4d768708708330c1b141/805c04b8c592400eb28358eb81f1a145.jpg, createdBy=4a299119890, createdName=Dehors, createdTime=Tue Jan 02 18:33:59 CST 2024, time=2024-01-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192926, encodeId=69e621929264f, content=大佬们,现在版面费是第三方收取么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqpapZYXCJZ2AkkJ5Gps0ysAzZE4zgb2VXFGn2ZHyMj98TIQpsx3yxTicaD0m42xk9m1vRtBPgS7TQ/132, createdBy=4b552425875, createdName=ms7957059236203375, createdTime=Wed Mar 13 10:38:38 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2193635, encodeId=dd73219363538, content=偏重的研究方向:肿瘤<br>经验分享:有问题可以聊聊 可稳妥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Sat Mar 16 21:13:02 CST 2024, time=2024-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182530, encodeId=53c4218253026, content=偏重的研究方向:临床预测模型<br>经验分享:Submission under peer review<br>14 Dec 2023<br>Submission passed technical check<br>14 Dec 2023<br>Amendment received<br>14 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>Submission under peer review一直没有变化,是不是连审稿人都没邀请啊?不会被忘了吧。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa979032293, createdName=ms2000000264173426, createdTime=Fri Jan 19 00:15:20 CST 2024, time=2024-01-19, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2192756, encodeId=a4772192e56a0, content=偏重的研究方向:肿瘤<br>经验分享:比较nice,有办法可以accept,没投的可以聊聊,速度也挺快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Tue Mar 12 14:18:54 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193260, encodeId=55b72193260af, content=偏重的研究方向:肿瘤<br>经验分享:最近大家的状态都乱码了,大家都有点慌,我发邮件问了编辑,编辑也回复的,附在下边。我的理解是今年sr的系统应该是换状态了,现在的这个状态应该是包含了之前我们见过的很多状态,耐心等待吧,有消息应该会通知到邮箱
Dear Prof.,
Thank you for your email and please accept my sincerest apologies for the lack of update on your paper. Your manuscript has cleared the quality check stage and it is going through the peer review process. So afar we have secured one reviewer and the editor is inviting more reviewers in order to sure at least one more reviewer.
I completely understand that this delay is unacceptable and I cannot apologise enough for this. Please be assured that we are always in regular contact with the handling Editor and doing all we can to ensure your manuscript is expedited through the publishing process as swiftly as possible. We hope to get a decision to you soon and your patience while we do this will be greatly appreciated.
Please do not hesitate to contact us again if there is anything we may be able to help you with, and please accept my apologies once more.
Kind Regards,
Prasad Bhalerao, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=611f6487300, createdName=ms4000001202980961, createdTime=Thu Mar 14 19:13:57 CST 2024, time=2024-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192732, encodeId=d4962192e3210, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:分子;细胞<br>经验分享:23年9月开始投的,一直到现在24.3.12都一直没用动静,之前是18个同行评审,现在也看不见,中途出现过一个审稿人意见,只有一个,但是系统上看不见,现在也没有显示有审稿意见了,这也太慢了,都想投其他期刊了,又感觉等这么久就白费了<br>Submission history<br>Peer review<br>Submission status Date<br>Submission under peer review<br>06 Oct 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>06 Oct 2023<br>Amendment received<br>06 Oct 2023<br>Submission is under technical check<br>18 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>18 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4248263748, createdName=ms9000001661382603, createdTime=Tue Mar 12 11:13:29 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2173392, encodeId=267721e339254, content=想问下大佬们,到这个阶段之后,后续会有editer has been invited 或者多少多少reviewers has been invited吗?还是就过几个礼拜直接到decision了?
We will now find the most suitable editor to manage the next steps of your submission. If your submission is successful, they will invite reviewers to peer review your work. This process can take a few weeks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Wed Dec 06 23:30:26 CST 2023, time=2023-12-06, status=1, ipAttribution=上海)]
[GetPortalCommentsPageByObjectIdResponse(id=2194005, encodeId=c72021940051b, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/a740eabd21e54f09ba6a274bd9a74985-9iEgmowY5Bs2.jpg, createdBy=7dec9219365, createdName=Tou18389577351, createdTime=Tue Mar 19 09:33:59 CST 2024, time=1小时前, status=0, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193895, encodeId=aa8c2193895cc, content=审稿速度:24.0 | 投稿命中率:50.0<br>偏重的研究方向:数据分析<br>经验分享:用了一年多时间,太不容易了,分享一下过程吧<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>18 Mar 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>18 Mar 2024<br>Submission under peer review<br>25 Feb 2024<br>Submission passed technical check<br>25 Feb 2024<br>Amendment received<br>24 Feb 2024<br>Revision received<br>23 Feb 2024<br>Submission under peer review<br>21 Feb 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>21 Feb 2023<br>Submission is under technical check<br>20 Feb 2023<br>Submission received<br>Submission status Date<br>Submission received<br>20 Feb 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f83c4883792, createdName=SENOMEGA, createdTime=Mon Mar 18 15:21:02 CST 2024, time=19小时前, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2178836, encodeId=212721e883660, content=偏重的研究方向:生物信息学;肿瘤;Cancer<br>经验分享:- [ ] 2023.12.26 submission received
- [ ] 2023.12.26 submission is under technical check
- [ ] 2023.12.27 submission passed technical check
- [ ] 2023.12.27 editor invited
- [ ] 2023.12.27 editor assigned
- [ ] 2023.12.27 reviewers invited(3)
- [ ] 2023.12.27 1 reviewer(s) accepted
- [ ] 2023.12.30 2 reviewer(s) accepted (Awaiting their report), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240102/21c3548d3cdf4d768708708330c1b141/805c04b8c592400eb28358eb81f1a145.jpg, createdBy=4a299119890, createdName=Dehors, createdTime=Tue Jan 02 18:33:59 CST 2024, time=2024-01-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192926, encodeId=69e621929264f, content=大佬们,现在版面费是第三方收取么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqpapZYXCJZ2AkkJ5Gps0ysAzZE4zgb2VXFGn2ZHyMj98TIQpsx3yxTicaD0m42xk9m1vRtBPgS7TQ/132, createdBy=4b552425875, createdName=ms7957059236203375, createdTime=Wed Mar 13 10:38:38 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2193635, encodeId=dd73219363538, content=偏重的研究方向:肿瘤<br>经验分享:有问题可以聊聊 可稳妥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Sat Mar 16 21:13:02 CST 2024, time=2024-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182530, encodeId=53c4218253026, content=偏重的研究方向:临床预测模型<br>经验分享:Submission under peer review<br>14 Dec 2023<br>Submission passed technical check<br>14 Dec 2023<br>Amendment received<br>14 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>Submission under peer review一直没有变化,是不是连审稿人都没邀请啊?不会被忘了吧。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa979032293, createdName=ms2000000264173426, createdTime=Fri Jan 19 00:15:20 CST 2024, time=2024-01-19, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2192756, encodeId=a4772192e56a0, content=偏重的研究方向:肿瘤<br>经验分享:比较nice,有办法可以accept,没投的可以聊聊,速度也挺快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Tue Mar 12 14:18:54 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193260, encodeId=55b72193260af, content=偏重的研究方向:肿瘤<br>经验分享:最近大家的状态都乱码了,大家都有点慌,我发邮件问了编辑,编辑也回复的,附在下边。我的理解是今年sr的系统应该是换状态了,现在的这个状态应该是包含了之前我们见过的很多状态,耐心等待吧,有消息应该会通知到邮箱
Dear Prof.,
Thank you for your email and please accept my sincerest apologies for the lack of update on your paper. Your manuscript has cleared the quality check stage and it is going through the peer review process. So afar we have secured one reviewer and the editor is inviting more reviewers in order to sure at least one more reviewer.
I completely understand that this delay is unacceptable and I cannot apologise enough for this. Please be assured that we are always in regular contact with the handling Editor and doing all we can to ensure your manuscript is expedited through the publishing process as swiftly as possible. We hope to get a decision to you soon and your patience while we do this will be greatly appreciated.
Please do not hesitate to contact us again if there is anything we may be able to help you with, and please accept my apologies once more.
Kind Regards,
Prasad Bhalerao, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=611f6487300, createdName=ms4000001202980961, createdTime=Thu Mar 14 19:13:57 CST 2024, time=2024-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192732, encodeId=d4962192e3210, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:分子;细胞<br>经验分享:23年9月开始投的,一直到现在24.3.12都一直没用动静,之前是18个同行评审,现在也看不见,中途出现过一个审稿人意见,只有一个,但是系统上看不见,现在也没有显示有审稿意见了,这也太慢了,都想投其他期刊了,又感觉等这么久就白费了<br>Submission history<br>Peer review<br>Submission status Date<br>Submission under peer review<br>06 Oct 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>06 Oct 2023<br>Amendment received<br>06 Oct 2023<br>Submission is under technical check<br>18 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>18 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4248263748, createdName=ms9000001661382603, createdTime=Tue Mar 12 11:13:29 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2173392, encodeId=267721e339254, content=想问下大佬们,到这个阶段之后,后续会有editer has been invited 或者多少多少reviewers has been invited吗?还是就过几个礼拜直接到decision了?
We will now find the most suitable editor to manage the next steps of your submission. If your submission is successful, they will invite reviewers to peer review your work. This process can take a few weeks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Wed Dec 06 23:30:26 CST 2023, time=2023-12-06, status=1, ipAttribution=上海)]
偏重的研究方向:临床预测模型 经验分享:Submission under peer review 14 Dec 2023 Submission passed technical check 14 Dec 2023 Amendment received 14 Dec 2023 Amendment received 07 Dec 2023 Amendment received 07 Dec 2023 Submission is under technical check 04 Dec 2023 Submission received Submission status Date Submission received 04 Dec 2023 Submission under peer review一直没有变化,是不是连审稿人都没邀请啊?不会被忘了吧。。。
[GetPortalCommentsPageByObjectIdResponse(id=2194005, encodeId=c72021940051b, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/a740eabd21e54f09ba6a274bd9a74985-9iEgmowY5Bs2.jpg, createdBy=7dec9219365, createdName=Tou18389577351, createdTime=Tue Mar 19 09:33:59 CST 2024, time=1小时前, status=0, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193895, encodeId=aa8c2193895cc, content=审稿速度:24.0 | 投稿命中率:50.0<br>偏重的研究方向:数据分析<br>经验分享:用了一年多时间,太不容易了,分享一下过程吧<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>18 Mar 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>18 Mar 2024<br>Submission under peer review<br>25 Feb 2024<br>Submission passed technical check<br>25 Feb 2024<br>Amendment received<br>24 Feb 2024<br>Revision received<br>23 Feb 2024<br>Submission under peer review<br>21 Feb 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>21 Feb 2023<br>Submission is under technical check<br>20 Feb 2023<br>Submission received<br>Submission status Date<br>Submission received<br>20 Feb 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f83c4883792, createdName=SENOMEGA, createdTime=Mon Mar 18 15:21:02 CST 2024, time=19小时前, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2178836, encodeId=212721e883660, content=偏重的研究方向:生物信息学;肿瘤;Cancer<br>经验分享:- [ ] 2023.12.26 submission received
- [ ] 2023.12.26 submission is under technical check
- [ ] 2023.12.27 submission passed technical check
- [ ] 2023.12.27 editor invited
- [ ] 2023.12.27 editor assigned
- [ ] 2023.12.27 reviewers invited(3)
- [ ] 2023.12.27 1 reviewer(s) accepted
- [ ] 2023.12.30 2 reviewer(s) accepted (Awaiting their report), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240102/21c3548d3cdf4d768708708330c1b141/805c04b8c592400eb28358eb81f1a145.jpg, createdBy=4a299119890, createdName=Dehors, createdTime=Tue Jan 02 18:33:59 CST 2024, time=2024-01-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192926, encodeId=69e621929264f, content=大佬们,现在版面费是第三方收取么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqpapZYXCJZ2AkkJ5Gps0ysAzZE4zgb2VXFGn2ZHyMj98TIQpsx3yxTicaD0m42xk9m1vRtBPgS7TQ/132, createdBy=4b552425875, createdName=ms7957059236203375, createdTime=Wed Mar 13 10:38:38 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2193635, encodeId=dd73219363538, content=偏重的研究方向:肿瘤<br>经验分享:有问题可以聊聊 可稳妥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Sat Mar 16 21:13:02 CST 2024, time=2024-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182530, encodeId=53c4218253026, content=偏重的研究方向:临床预测模型<br>经验分享:Submission under peer review<br>14 Dec 2023<br>Submission passed technical check<br>14 Dec 2023<br>Amendment received<br>14 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>Submission under peer review一直没有变化,是不是连审稿人都没邀请啊?不会被忘了吧。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa979032293, createdName=ms2000000264173426, createdTime=Fri Jan 19 00:15:20 CST 2024, time=2024-01-19, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2192756, encodeId=a4772192e56a0, content=偏重的研究方向:肿瘤<br>经验分享:比较nice,有办法可以accept,没投的可以聊聊,速度也挺快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Tue Mar 12 14:18:54 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193260, encodeId=55b72193260af, content=偏重的研究方向:肿瘤<br>经验分享:最近大家的状态都乱码了,大家都有点慌,我发邮件问了编辑,编辑也回复的,附在下边。我的理解是今年sr的系统应该是换状态了,现在的这个状态应该是包含了之前我们见过的很多状态,耐心等待吧,有消息应该会通知到邮箱
Dear Prof.,
Thank you for your email and please accept my sincerest apologies for the lack of update on your paper. Your manuscript has cleared the quality check stage and it is going through the peer review process. So afar we have secured one reviewer and the editor is inviting more reviewers in order to sure at least one more reviewer.
I completely understand that this delay is unacceptable and I cannot apologise enough for this. Please be assured that we are always in regular contact with the handling Editor and doing all we can to ensure your manuscript is expedited through the publishing process as swiftly as possible. We hope to get a decision to you soon and your patience while we do this will be greatly appreciated.
Please do not hesitate to contact us again if there is anything we may be able to help you with, and please accept my apologies once more.
Kind Regards,
Prasad Bhalerao, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=611f6487300, createdName=ms4000001202980961, createdTime=Thu Mar 14 19:13:57 CST 2024, time=2024-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192732, encodeId=d4962192e3210, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:分子;细胞<br>经验分享:23年9月开始投的,一直到现在24.3.12都一直没用动静,之前是18个同行评审,现在也看不见,中途出现过一个审稿人意见,只有一个,但是系统上看不见,现在也没有显示有审稿意见了,这也太慢了,都想投其他期刊了,又感觉等这么久就白费了<br>Submission history<br>Peer review<br>Submission status Date<br>Submission under peer review<br>06 Oct 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>06 Oct 2023<br>Amendment received<br>06 Oct 2023<br>Submission is under technical check<br>18 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>18 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4248263748, createdName=ms9000001661382603, createdTime=Tue Mar 12 11:13:29 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2173392, encodeId=267721e339254, content=想问下大佬们,到这个阶段之后,后续会有editer has been invited 或者多少多少reviewers has been invited吗?还是就过几个礼拜直接到decision了?
We will now find the most suitable editor to manage the next steps of your submission. If your submission is successful, they will invite reviewers to peer review your work. This process can take a few weeks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Wed Dec 06 23:30:26 CST 2023, time=2023-12-06, status=1, ipAttribution=上海)]
[GetPortalCommentsPageByObjectIdResponse(id=2194005, encodeId=c72021940051b, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/a740eabd21e54f09ba6a274bd9a74985-9iEgmowY5Bs2.jpg, createdBy=7dec9219365, createdName=Tou18389577351, createdTime=Tue Mar 19 09:33:59 CST 2024, time=1小时前, status=0, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193895, encodeId=aa8c2193895cc, content=审稿速度:24.0 | 投稿命中率:50.0<br>偏重的研究方向:数据分析<br>经验分享:用了一年多时间,太不容易了,分享一下过程吧<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>18 Mar 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>18 Mar 2024<br>Submission under peer review<br>25 Feb 2024<br>Submission passed technical check<br>25 Feb 2024<br>Amendment received<br>24 Feb 2024<br>Revision received<br>23 Feb 2024<br>Submission under peer review<br>21 Feb 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>21 Feb 2023<br>Submission is under technical check<br>20 Feb 2023<br>Submission received<br>Submission status Date<br>Submission received<br>20 Feb 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f83c4883792, createdName=SENOMEGA, createdTime=Mon Mar 18 15:21:02 CST 2024, time=19小时前, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2178836, encodeId=212721e883660, content=偏重的研究方向:生物信息学;肿瘤;Cancer<br>经验分享:- [ ] 2023.12.26 submission received
- [ ] 2023.12.26 submission is under technical check
- [ ] 2023.12.27 submission passed technical check
- [ ] 2023.12.27 editor invited
- [ ] 2023.12.27 editor assigned
- [ ] 2023.12.27 reviewers invited(3)
- [ ] 2023.12.27 1 reviewer(s) accepted
- [ ] 2023.12.30 2 reviewer(s) accepted (Awaiting their report), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240102/21c3548d3cdf4d768708708330c1b141/805c04b8c592400eb28358eb81f1a145.jpg, createdBy=4a299119890, createdName=Dehors, createdTime=Tue Jan 02 18:33:59 CST 2024, time=2024-01-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192926, encodeId=69e621929264f, content=大佬们,现在版面费是第三方收取么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqpapZYXCJZ2AkkJ5Gps0ysAzZE4zgb2VXFGn2ZHyMj98TIQpsx3yxTicaD0m42xk9m1vRtBPgS7TQ/132, createdBy=4b552425875, createdName=ms7957059236203375, createdTime=Wed Mar 13 10:38:38 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2193635, encodeId=dd73219363538, content=偏重的研究方向:肿瘤<br>经验分享:有问题可以聊聊 可稳妥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Sat Mar 16 21:13:02 CST 2024, time=2024-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182530, encodeId=53c4218253026, content=偏重的研究方向:临床预测模型<br>经验分享:Submission under peer review<br>14 Dec 2023<br>Submission passed technical check<br>14 Dec 2023<br>Amendment received<br>14 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>Submission under peer review一直没有变化,是不是连审稿人都没邀请啊?不会被忘了吧。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa979032293, createdName=ms2000000264173426, createdTime=Fri Jan 19 00:15:20 CST 2024, time=2024-01-19, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2192756, encodeId=a4772192e56a0, content=偏重的研究方向:肿瘤<br>经验分享:比较nice,有办法可以accept,没投的可以聊聊,速度也挺快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Tue Mar 12 14:18:54 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193260, encodeId=55b72193260af, content=偏重的研究方向:肿瘤<br>经验分享:最近大家的状态都乱码了,大家都有点慌,我发邮件问了编辑,编辑也回复的,附在下边。我的理解是今年sr的系统应该是换状态了,现在的这个状态应该是包含了之前我们见过的很多状态,耐心等待吧,有消息应该会通知到邮箱
Dear Prof.,
Thank you for your email and please accept my sincerest apologies for the lack of update on your paper. Your manuscript has cleared the quality check stage and it is going through the peer review process. So afar we have secured one reviewer and the editor is inviting more reviewers in order to sure at least one more reviewer.
I completely understand that this delay is unacceptable and I cannot apologise enough for this. Please be assured that we are always in regular contact with the handling Editor and doing all we can to ensure your manuscript is expedited through the publishing process as swiftly as possible. We hope to get a decision to you soon and your patience while we do this will be greatly appreciated.
Please do not hesitate to contact us again if there is anything we may be able to help you with, and please accept my apologies once more.
Kind Regards,
Prasad Bhalerao, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=611f6487300, createdName=ms4000001202980961, createdTime=Thu Mar 14 19:13:57 CST 2024, time=2024-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192732, encodeId=d4962192e3210, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:分子;细胞<br>经验分享:23年9月开始投的,一直到现在24.3.12都一直没用动静,之前是18个同行评审,现在也看不见,中途出现过一个审稿人意见,只有一个,但是系统上看不见,现在也没有显示有审稿意见了,这也太慢了,都想投其他期刊了,又感觉等这么久就白费了<br>Submission history<br>Peer review<br>Submission status Date<br>Submission under peer review<br>06 Oct 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>06 Oct 2023<br>Amendment received<br>06 Oct 2023<br>Submission is under technical check<br>18 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>18 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4248263748, createdName=ms9000001661382603, createdTime=Tue Mar 12 11:13:29 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2173392, encodeId=267721e339254, content=想问下大佬们,到这个阶段之后,后续会有editer has been invited 或者多少多少reviewers has been invited吗?还是就过几个礼拜直接到decision了?
We will now find the most suitable editor to manage the next steps of your submission. If your submission is successful, they will invite reviewers to peer review your work. This process can take a few weeks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Wed Dec 06 23:30:26 CST 2023, time=2023-12-06, status=1, ipAttribution=上海)]
偏重的研究方向:肿瘤 经验分享:最近大家的状态都乱码了,大家都有点慌,我发邮件问了编辑,编辑也回复的,附在下边。我的理解是今年sr的系统应该是换状态了,现在的这个状态应该是包含了之前我们见过的很多状态,耐心等待吧,有消息应该会通知到邮箱
Dear Prof.,
Thank you for your email and please accept my sincerest apologies for the lack of update on your paper. Your manuscript has cleared the quality check stage and it is going through the peer review process. So afar we have secured one reviewer and the editor is inviting more reviewers in order to sure at least one more reviewer.
I completely understand that this delay is unacceptable and I cannot apologise enough for this. Please be assured that we are always in regular contact with the handling Editor and doing all we can to ensure your manuscript is expedited through the publishing process as swiftly as possible. We hope to get a decision to you soon and your patience while we do this will be greatly appreciated.
Please do not hesitate to contact us again if there is anything we may be able to help you with, and please accept my apologies once more.
Kind Regards,
Prasad Bhalerao
[GetPortalCommentsPageByObjectIdResponse(id=2194005, encodeId=c72021940051b, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/a740eabd21e54f09ba6a274bd9a74985-9iEgmowY5Bs2.jpg, createdBy=7dec9219365, createdName=Tou18389577351, createdTime=Tue Mar 19 09:33:59 CST 2024, time=1小时前, status=0, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193895, encodeId=aa8c2193895cc, content=审稿速度:24.0 | 投稿命中率:50.0<br>偏重的研究方向:数据分析<br>经验分享:用了一年多时间,太不容易了,分享一下过程吧<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>18 Mar 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>18 Mar 2024<br>Submission under peer review<br>25 Feb 2024<br>Submission passed technical check<br>25 Feb 2024<br>Amendment received<br>24 Feb 2024<br>Revision received<br>23 Feb 2024<br>Submission under peer review<br>21 Feb 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>21 Feb 2023<br>Submission is under technical check<br>20 Feb 2023<br>Submission received<br>Submission status Date<br>Submission received<br>20 Feb 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f83c4883792, createdName=SENOMEGA, createdTime=Mon Mar 18 15:21:02 CST 2024, time=19小时前, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2178836, encodeId=212721e883660, content=偏重的研究方向:生物信息学;肿瘤;Cancer<br>经验分享:- [ ] 2023.12.26 submission received
- [ ] 2023.12.26 submission is under technical check
- [ ] 2023.12.27 submission passed technical check
- [ ] 2023.12.27 editor invited
- [ ] 2023.12.27 editor assigned
- [ ] 2023.12.27 reviewers invited(3)
- [ ] 2023.12.27 1 reviewer(s) accepted
- [ ] 2023.12.30 2 reviewer(s) accepted (Awaiting their report), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240102/21c3548d3cdf4d768708708330c1b141/805c04b8c592400eb28358eb81f1a145.jpg, createdBy=4a299119890, createdName=Dehors, createdTime=Tue Jan 02 18:33:59 CST 2024, time=2024-01-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192926, encodeId=69e621929264f, content=大佬们,现在版面费是第三方收取么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqpapZYXCJZ2AkkJ5Gps0ysAzZE4zgb2VXFGn2ZHyMj98TIQpsx3yxTicaD0m42xk9m1vRtBPgS7TQ/132, createdBy=4b552425875, createdName=ms7957059236203375, createdTime=Wed Mar 13 10:38:38 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2193635, encodeId=dd73219363538, content=偏重的研究方向:肿瘤<br>经验分享:有问题可以聊聊 可稳妥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Sat Mar 16 21:13:02 CST 2024, time=2024-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182530, encodeId=53c4218253026, content=偏重的研究方向:临床预测模型<br>经验分享:Submission under peer review<br>14 Dec 2023<br>Submission passed technical check<br>14 Dec 2023<br>Amendment received<br>14 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>Submission under peer review一直没有变化,是不是连审稿人都没邀请啊?不会被忘了吧。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa979032293, createdName=ms2000000264173426, createdTime=Fri Jan 19 00:15:20 CST 2024, time=2024-01-19, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2192756, encodeId=a4772192e56a0, content=偏重的研究方向:肿瘤<br>经验分享:比较nice,有办法可以accept,没投的可以聊聊,速度也挺快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Tue Mar 12 14:18:54 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193260, encodeId=55b72193260af, content=偏重的研究方向:肿瘤<br>经验分享:最近大家的状态都乱码了,大家都有点慌,我发邮件问了编辑,编辑也回复的,附在下边。我的理解是今年sr的系统应该是换状态了,现在的这个状态应该是包含了之前我们见过的很多状态,耐心等待吧,有消息应该会通知到邮箱
Dear Prof.,
Thank you for your email and please accept my sincerest apologies for the lack of update on your paper. Your manuscript has cleared the quality check stage and it is going through the peer review process. So afar we have secured one reviewer and the editor is inviting more reviewers in order to sure at least one more reviewer.
I completely understand that this delay is unacceptable and I cannot apologise enough for this. Please be assured that we are always in regular contact with the handling Editor and doing all we can to ensure your manuscript is expedited through the publishing process as swiftly as possible. We hope to get a decision to you soon and your patience while we do this will be greatly appreciated.
Please do not hesitate to contact us again if there is anything we may be able to help you with, and please accept my apologies once more.
Kind Regards,
Prasad Bhalerao, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=611f6487300, createdName=ms4000001202980961, createdTime=Thu Mar 14 19:13:57 CST 2024, time=2024-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192732, encodeId=d4962192e3210, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:分子;细胞<br>经验分享:23年9月开始投的,一直到现在24.3.12都一直没用动静,之前是18个同行评审,现在也看不见,中途出现过一个审稿人意见,只有一个,但是系统上看不见,现在也没有显示有审稿意见了,这也太慢了,都想投其他期刊了,又感觉等这么久就白费了<br>Submission history<br>Peer review<br>Submission status Date<br>Submission under peer review<br>06 Oct 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>06 Oct 2023<br>Amendment received<br>06 Oct 2023<br>Submission is under technical check<br>18 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>18 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4248263748, createdName=ms9000001661382603, createdTime=Tue Mar 12 11:13:29 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2173392, encodeId=267721e339254, content=想问下大佬们,到这个阶段之后,后续会有editer has been invited 或者多少多少reviewers has been invited吗?还是就过几个礼拜直接到decision了?
We will now find the most suitable editor to manage the next steps of your submission. If your submission is successful, they will invite reviewers to peer review your work. This process can take a few weeks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Wed Dec 06 23:30:26 CST 2023, time=2023-12-06, status=1, ipAttribution=上海)]
审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向:分子;细胞 经验分享:23年9月开始投的,一直到现在24.3.12都一直没用动静,之前是18个同行评审,现在也看不见,中途出现过一个审稿人意见,只有一个,但是系统上看不见,现在也没有显示有审稿意见了,这也太慢了,都想投其他期刊了,又感觉等这么久就白费了 Submission history Peer review Submission status Date Submission under peer review 06 Oct 2023 Technical check Submission status Date Submission passed technical check 06 Oct 2023 Amendment received 06 Oct 2023 Submission is under technical check 18 Sep 2023 Submission received Submission status Date Submission received 18 Sep 2023
[GetPortalCommentsPageByObjectIdResponse(id=2194005, encodeId=c72021940051b, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/a740eabd21e54f09ba6a274bd9a74985-9iEgmowY5Bs2.jpg, createdBy=7dec9219365, createdName=Tou18389577351, createdTime=Tue Mar 19 09:33:59 CST 2024, time=1小时前, status=0, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193895, encodeId=aa8c2193895cc, content=审稿速度:24.0 | 投稿命中率:50.0<br>偏重的研究方向:数据分析<br>经验分享:用了一年多时间,太不容易了,分享一下过程吧<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>18 Mar 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>18 Mar 2024<br>Submission under peer review<br>25 Feb 2024<br>Submission passed technical check<br>25 Feb 2024<br>Amendment received<br>24 Feb 2024<br>Revision received<br>23 Feb 2024<br>Submission under peer review<br>21 Feb 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>21 Feb 2023<br>Submission is under technical check<br>20 Feb 2023<br>Submission received<br>Submission status Date<br>Submission received<br>20 Feb 2023<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f83c4883792, createdName=SENOMEGA, createdTime=Mon Mar 18 15:21:02 CST 2024, time=19小时前, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2178836, encodeId=212721e883660, content=偏重的研究方向:生物信息学;肿瘤;Cancer<br>经验分享:- [ ] 2023.12.26 submission received
- [ ] 2023.12.26 submission is under technical check
- [ ] 2023.12.27 submission passed technical check
- [ ] 2023.12.27 editor invited
- [ ] 2023.12.27 editor assigned
- [ ] 2023.12.27 reviewers invited(3)
- [ ] 2023.12.27 1 reviewer(s) accepted
- [ ] 2023.12.30 2 reviewer(s) accepted (Awaiting their report), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240102/21c3548d3cdf4d768708708330c1b141/805c04b8c592400eb28358eb81f1a145.jpg, createdBy=4a299119890, createdName=Dehors, createdTime=Tue Jan 02 18:33:59 CST 2024, time=2024-01-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192926, encodeId=69e621929264f, content=大佬们,现在版面费是第三方收取么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqpapZYXCJZ2AkkJ5Gps0ysAzZE4zgb2VXFGn2ZHyMj98TIQpsx3yxTicaD0m42xk9m1vRtBPgS7TQ/132, createdBy=4b552425875, createdName=ms7957059236203375, createdTime=Wed Mar 13 10:38:38 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2193635, encodeId=dd73219363538, content=偏重的研究方向:肿瘤<br>经验分享:有问题可以聊聊 可稳妥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Sat Mar 16 21:13:02 CST 2024, time=2024-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182530, encodeId=53c4218253026, content=偏重的研究方向:临床预测模型<br>经验分享:Submission under peer review<br>14 Dec 2023<br>Submission passed technical check<br>14 Dec 2023<br>Amendment received<br>14 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Amendment received<br>07 Dec 2023<br>Submission is under technical check<br>04 Dec 2023<br>Submission received<br>Submission status Date<br>Submission received<br>04 Dec 2023<br>Submission under peer review一直没有变化,是不是连审稿人都没邀请啊?不会被忘了吧。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa979032293, createdName=ms2000000264173426, createdTime=Fri Jan 19 00:15:20 CST 2024, time=2024-01-19, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2192756, encodeId=a4772192e56a0, content=偏重的研究方向:肿瘤<br>经验分享:比较nice,有办法可以accept,没投的可以聊聊,速度也挺快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Tue Mar 12 14:18:54 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193260, encodeId=55b72193260af, content=偏重的研究方向:肿瘤<br>经验分享:最近大家的状态都乱码了,大家都有点慌,我发邮件问了编辑,编辑也回复的,附在下边。我的理解是今年sr的系统应该是换状态了,现在的这个状态应该是包含了之前我们见过的很多状态,耐心等待吧,有消息应该会通知到邮箱
Dear Prof.,
Thank you for your email and please accept my sincerest apologies for the lack of update on your paper. Your manuscript has cleared the quality check stage and it is going through the peer review process. So afar we have secured one reviewer and the editor is inviting more reviewers in order to sure at least one more reviewer.
I completely understand that this delay is unacceptable and I cannot apologise enough for this. Please be assured that we are always in regular contact with the handling Editor and doing all we can to ensure your manuscript is expedited through the publishing process as swiftly as possible. We hope to get a decision to you soon and your patience while we do this will be greatly appreciated.
Please do not hesitate to contact us again if there is anything we may be able to help you with, and please accept my apologies once more.
Kind Regards,
Prasad Bhalerao, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=611f6487300, createdName=ms4000001202980961, createdTime=Thu Mar 14 19:13:57 CST 2024, time=2024-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192732, encodeId=d4962192e3210, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:分子;细胞<br>经验分享:23年9月开始投的,一直到现在24.3.12都一直没用动静,之前是18个同行评审,现在也看不见,中途出现过一个审稿人意见,只有一个,但是系统上看不见,现在也没有显示有审稿意见了,这也太慢了,都想投其他期刊了,又感觉等这么久就白费了<br>Submission history<br>Peer review<br>Submission status Date<br>Submission under peer review<br>06 Oct 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>06 Oct 2023<br>Amendment received<br>06 Oct 2023<br>Submission is under technical check<br>18 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>18 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4248263748, createdName=ms9000001661382603, createdTime=Tue Mar 12 11:13:29 CST 2024, time=2024-03-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2173392, encodeId=267721e339254, content=想问下大佬们,到这个阶段之后,后续会有editer has been invited 或者多少多少reviewers has been invited吗?还是就过几个礼拜直接到decision了?
We will now find the most suitable editor to manage the next steps of your submission. If your submission is successful, they will invite reviewers to peer review your work. This process can take a few weeks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230712/7b1f2dc9a324479e9877047bc3d85ecd/b95cd487c3e24b4d8bfa2fc6ab30880c.jpg, createdBy=aed48754576, createdName=发大文章带我一个二十作吧, createdTime=Wed Dec 06 23:30:26 CST 2023, time=2023-12-06, status=1, ipAttribution=上海)]
想问下大佬们,到这个阶段之后,后续会有editer has been invited 或者多少多少reviewers has been invited吗?还是就过几个礼拜直接到decision了?
We will now find the most suitable editor to manage the next steps of your submission. If your submission is successful, they will invite reviewers to peer review your work. This process can take a few weeks.
前往app查看评论内容
0 0
审稿速度:24.0 | 投稿命中率:50.0
偏重的研究方向:数据分析
经验分享:用了一年多时间,太不容易了,分享一下过程吧
Publishing and rights
Submission status Date
Submission is in publishing and rights
18 Mar 2024
Peer review
Submission status Date
Submission accepted
18 Mar 2024
Submission under peer review
25 Feb 2024
Submission passed technical check
25 Feb 2024
Amendment received
24 Feb 2024
Revision received
23 Feb 2024
Submission under peer review
21 Feb 2023
Technical check
Submission status Date
Submission passed technical check
21 Feb 2023
Submission is under technical check
20 Feb 2023
Submission received
Submission status Date
Submission received
20 Feb 2023
3
偏重的研究方向:生物信息学;肿瘤;Cancer
经验分享:- [ ] 2023.12.26 submission received - [ ] 2023.12.26 submission is under technical check - [ ] 2023.12.27 submission passed technical check - [ ] 2023.12.27 editor invited - [ ] 2023.12.27 editor assigned - [ ] 2023.12.27 reviewers invited(3) - [ ] 2023.12.27 1 reviewer(s) accepted - [ ] 2023.12.30 2 reviewer(s) accepted (Awaiting their report)
51
大佬们,现在版面费是第三方收取么?
9
偏重的研究方向:肿瘤
经验分享:有问题可以聊聊 可稳妥
2
偏重的研究方向:临床预测模型
经验分享:Submission under peer review
14 Dec 2023
Submission passed technical check
14 Dec 2023
Amendment received
14 Dec 2023
Amendment received
07 Dec 2023
Amendment received
07 Dec 2023
Submission is under technical check
04 Dec 2023
Submission received
Submission status Date
Submission received
04 Dec 2023
Submission under peer review一直没有变化,是不是连审稿人都没邀请啊?不会被忘了吧。。。
22
偏重的研究方向:肿瘤
经验分享:比较nice,有办法可以accept,没投的可以聊聊,速度也挺快
56
偏重的研究方向:肿瘤
经验分享:最近大家的状态都乱码了,大家都有点慌,我发邮件问了编辑,编辑也回复的,附在下边。我的理解是今年sr的系统应该是换状态了,现在的这个状态应该是包含了之前我们见过的很多状态,耐心等待吧,有消息应该会通知到邮箱 Dear Prof., Thank you for your email and please accept my sincerest apologies for the lack of update on your paper. Your manuscript has cleared the quality check stage and it is going through the peer review process. So afar we have secured one reviewer and the editor is inviting more reviewers in order to sure at least one more reviewer. I completely understand that this delay is unacceptable and I cannot apologise enough for this. Please be assured that we are always in regular contact with the handling Editor and doing all we can to ensure your manuscript is expedited through the publishing process as swiftly as possible. We hope to get a decision to you soon and your patience while we do this will be greatly appreciated. Please do not hesitate to contact us again if there is anything we may be able to help you with, and please accept my apologies once more. Kind Regards, Prasad Bhalerao
117
审稿速度:12.0 | 投稿命中率:5.0
偏重的研究方向:分子;细胞
经验分享:23年9月开始投的,一直到现在24.3.12都一直没用动静,之前是18个同行评审,现在也看不见,中途出现过一个审稿人意见,只有一个,但是系统上看不见,现在也没有显示有审稿意见了,这也太慢了,都想投其他期刊了,又感觉等这么久就白费了
Submission history
Peer review
Submission status Date
Submission under peer review
06 Oct 2023
Technical check
Submission status Date
Submission passed technical check
06 Oct 2023
Amendment received
06 Oct 2023
Submission is under technical check
18 Sep 2023
Submission received
Submission status Date
Submission received
18 Sep 2023
7
想问下大佬们,到这个阶段之后,后续会有editer has been invited 或者多少多少reviewers has been invited吗?还是就过几个礼拜直接到decision了? We will now find the most suitable editor to manage the next steps of your submission. If your submission is successful, they will invite reviewers to peer review your work. This process can take a few weeks.
39